CHICAGO, Sept. 2, 2011 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Cooper Companies (NYSE: COO), Johnson & Johnson (NYSE: JNJ), Novartis (NYSE: NVS), Joy Global Inc. (Nasdaq: JOYG) and Cameron International Corporation (NYSE: CAM).

(Logo:  http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Thursday's Analyst Blog:

Cooper Beats, but Profit Dips

The Cooper Companies (NYSE: COO), a company focused on contact lens and women's health, reported third-quarter fiscal 2011 (ended July 31) results with adjusted earnings per share of $1.15 comfortably beating both the Zacks Consensus Estimate of $1.08 and the year-ago earnings per share of 91 cents.

Net income (as reported) for the quarter stood at $38.1 million (or 78 cents a share), down 4% y/y, after the company recalled certain Avaira toric contact lenses and recognized a one-time charge.

Revenue Analysis

Company-wide revenues for the quarter increased 19% (12% in constant currency) year over year to $351.4 million, exceeding the Zacks Consensus Estimate of $332 million, driven mostly by solid growth in vision-related products.

Sales from the contact lens division ("CVI") were up 20% (11% in constant currency) year over year to $298.3 million. Sales were higher across the board with mainstay toric lenses (up 17%), single-use sphere lenses (higher 21%) and non-single-use sphere lenses (up 24%) doing well, while multifocal sales were up more marginally.

On a geographic basis, sales from EMEA and Asia-Pacific jumped 25% and 40%, respectively, and increased a more modest 7% in the Americas. On a material basis, sales of silicone hydrogel were up a significant 56% to $91.9 million while Proclear sales increased moderately by 14% to $80.7 million.   

The women's health segment ("CSI") continued to perform reasonably well with revenues rising 14% year over year (12% excluding acquisitions) to $53.1 million. Sales of this strategic business unit were bolstered by surgical procedures which increased 29% to $20.4 million.

Margin Trends

Cooper's gross margin dropped to 58% in the quarter from 60% a year ago, on account of a $14.2 million reserve for inventory and return provisions arising from the voluntary recall of select lots of Avaira toric lenses, on August 19, 2011. Gross margin was higher at 62% excluding this reserve. Operating margin dropped to 13% from 17% in the prior-year quarter due to the Avaira recall and the reversal of a one-time gain of $6.1 million. Excluding these adjustments, operating margin was 19%.

Financial Health

Cooper exited the quarter with cash and cash equivalents of only $7.9 million, up 143% year over year. The company continued with its de-leveraging trend as total debt fell 34.9% year over year, to $406.5 million in the quarter.

Cooper generated $87.4 million of operating cash flow in the quarter and spent $19.1 million on capital expenditure, yielding free cash flows of $68.3 million (up 17% year over year).

Outlook

Cooper amended its guidance for fiscal 2011 based on better prospects for contact lens sales. The company now forecasts adjusted earnings per share for the year in a higher range of $4.20 to $4.25 versus its earlier projection of $4.00 to $4.15. Revenue forecast for the year has also been slightly modified to a higher range of $1.320 billion to $1.335 billion versus the earlier forecast of $1.280 billion to $1.300 billion.

Revenues for the CVI and CSI divisions are projected in the range of $1,117 million to $1,127 million and $203 million to $208 million, respectively. Free cash flow has been forecast in a range of $200 million to $220 million, up from the earlier guidance of $190 million to $210 million.

Cooper said it expects revenues in the range of $350 million to $365 million with adjusted earnings per share between $1.19 and $1.24 per share in the fiscal fourth quarter. That comprises $300 million to $310 million in sales from CVI and $50 million to $55 million from CSI.

Cooper is a global medical products company specializing in a wide range of contact lenses for the vision correction market with a smaller strategic business unit for women's health. It reportedly holds the number three position in the $6 billion global contact lens industry.

Cooper is a leader in the high-margin toric lens market. It offers multiple designs of toric lenses, across a wide range of parameters, unlike some of its competitors, who offer toric lenses in a limited number of designs. The company is benefiting from strong demand for its Biofinity toric lenses.

However, Cooper faces formidable competition in each of its major product lines. Competition comes from globally well established contact lens makers such as Johnson & Johnson (NYSE: JNJ) and Novartis (NYSE: NVS). Depressed levels of consumer spending have heightened the competitive pressures on the company. Our Outperform recommendation on the stock is backed by a short-term Zacks #2 Rank (Buy).

Joy Global to Sell LeTourneau Unit

Mining equipment maker Joy Global Inc. (Nasdaq: JOYG) said it has agreed to sell the drilling products business of the recently acquired LeTourneau Technologies Inc. The company will sell the LeTourneau Technologies Drillings Systems and Offshore Products divisions to Cameron International Corporation (NYSE: CAM) for $375 million in cash.

The LeTourneau unit designs offshore jack-up drilling rigs and manufactures primary components for the rigs, along with drilling equipment for large land and offshore rigs. LeTourneau's products include elevating systems, skidding systems, cranes, top drives, rotary tables, draw works, mud pumps and rig control and power systems.

The boards of Cameron and Joy Global have unanimously approved the transaction. The companies expect to close the deal during the fourth quarter of 2011, pending customary closing conditions.

Joy Global's decision to sell the LeTourneau drilling products unit stemmed from its intention to focus on its core business of manufacturing surface and underground mining equipment. Also, the company expects this sale to expand its funding options to complete the planned acquisition of China-based International Mining Machinery Holdings Ltd.

As part of the deal, with Cameron, Joy Global will dispose the LeTourneau facilities in Houston and Vicksburg, Mississippi. However, it will retain a facility in Longview, Texas, where LeTourneau manufactures large capacity wheel loaders for the surface mining market.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

SOURCE Zacks Investment Research, Inc.

Copyright 2011 PR Newswire

Cooper Cameron (NYSE:CAM)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Cooper Cameron Charts.
Cooper Cameron (NYSE:CAM)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Cooper Cameron Charts.